Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative MedicineCell Therapy

PUBLISHER: Grand View Research | PRODUCT CODE: 1587569

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1587569

Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Allogeneic Therapies, Autologous Therapies), By Therapeutic Area (Oncology, Dermatology), By Country, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (5-User License)
USD 5950
Printable PDF (Enterprise License)
USD 7950

Add to Cart

Description

Table of Contents

List of Tables

Asia Pacific Cell Therapy Market Growth & Trends:

The Asia Pacific cell therapy market size is anticipated to reach USD 2.77 billion in 2030 and is expected to grow at a CAGR of 22.49% from 2025 to 2030 Rapid advancements in regenerative medicine are anticipated to provide effective solutions for chronic conditions. A substantial number of companies in the growing markets, such as India and South Korea, are striving to capitalize on the untapped opportunities in the market, thereby driving the market.

The growth is greatly benefitted by the fund and regulatory support from government bodies and regulatory agencies. For instance, in August 2020, the government of South Korea passed an Act on the Safety and Support of Advanced Regenerative Medical Treatment and Medicine to establish a regulatory system for patient safety during quality control and clinical trials, and to strengthen the regulatory support for regenerative medicine development.

The implementation of the act is expected to enhance clinical studies and approvals of regenerative medicine in South Korea. Furthermore, CAR-T and TCR T-cell therapies have already revolutionized hematologic cancer treatment. With the onset of the COVID-19 pandemic, scientists are deciphering its potential against the novel coronavirus. The concept of using T cells against chronic viral infections, such as HIV and hepatitis B, has already been proposed.

Based on the previous research insights, Singapore-based Duke-NUS medical school's emerging infectious diseases research program demonstrated the utility of these immunotherapies in treating patients with COVID-19 infection. Thus, an increase in research for use of cell therapies for COVID-19 treatment is expected to drive the market in Asian countries. In April 2021, a team of researchers from Japan used induced pluripotent stem cells (iPS) to find drugs that can effectively inhibit the coronavirus and other RNA viruses.

Asia Pacific Cell Therapy Market Report Highlights:

  • The segment is also driven by the rapid advances in stem cell research which exhibits the potential to effectively address the unmet demand of pharmaceutical and biotech entities, as well as healthcare professionals in disease management
  • On the other hand, the clinical use segment is expected to register a significant growth rate during the forecast period owing to the success of CAR-T and other cellular therapies in recent times
  • Furthermore, the declining price of stem cell therapy products is anticipated to boost sales in this segment coupled with rising demand for effective alternatives to conventional therapies against various chronic indications
  • This can be owed to relatively more application of cellular therapies in the management of various cancer types such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma
  • Japan has emerged as the leading Asian market, which can be attributed to its fast growth as a hub for research on regenerative medicine
  • On the other hand, Singapore and India are anticipated to witness the fastest growth over the forecast period owing to the presence of improving financing programs to support and advance cell therapy product development in the countries
Show more
Product Code: GVR-4-68039-450-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Therapy Type Segment
    • 1.1.2. Therapeutic Area Segment
  • 1.2. Country Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Primary Research
  • 1.6. Information or Data Analysis:
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rise in number of clinical studies for cellular therapies in Asia Pacific
      • 3.2.1.2. Expanding regenerative medicine landscape in Asian countries
      • 3.2.1.3. Introduction of novel platforms and technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Ethical concerns
      • 3.2.2.2. Clinical issues pertaining to development & implementation of cell therapy
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Therapy Type Business Analysis

  • 4.1. Therapy Type Segment Dashboard
  • 4.2. Asia Pacific cell therapy market: Therapy Type Movement Analysis
  • 4.3. Asia Pacific cell therapy market Size & Trend Analysis, by Therapy Type, 2018 to 2030 (USD Million)
  • 4.4. Allogeneic Therapies
    • 4.4.1. Allogeneic therapies market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Stem Cell Therapies
      • 4.4.2.1. Stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.2. Hematopoietic Stem Cell Therapies
        • 4.4.2.2.1. Hematopoietic stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.3. Mesenchymal Stem Cell Therapies
        • 4.4.2.3.1. Mesenchymal stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Non-stem Cell Therapies
      • 4.4.3.1. Non-stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.3.2. Keratinocytes & Fibroblast-based Therapies
        • 4.4.3.2.1. Keratinocytes & fibroblast-based therapies market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.4.3.3. Others
      • 4.4.3.4. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Autologous Therapies
    • 4.5.1. Autologous therapies market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Stem Cell Therapies
      • 4.5.2.1. Stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.2. BM, Blood, & Umbilical Cord-derived Stem Cells
        • 4.5.2.2.1. BM, blood, & umbilical cord-derived stem cells market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.3. Adipose derived cells
        • 4.5.2.3.1. Adipose derived cells market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.4. Others
        • 4.5.2.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Non-Stem Cell Therapies
      • 4.5.3.1. Non-stem cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.2. T-Cell Therapies
        • 4.5.3.2.1. T-Cell therapies market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.5.3.2.2. CAR T Cell Therapy
          • 4.5.3.2.2.1. CAR T cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.5.3.2.3. T Cell Receptor (TCR)-based
          • 4.5.3.2.3.1. T cell receptor (TCR)-based market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.3. Others
        • 4.5.3.3.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

  • 5.1. Therapeutic Area Segment Dashboard
  • 5.2. Asia Pacific cell therapy market Therapeutic Area Movement Analysis
  • 5.3. Asia Pacific cell therapy market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Cardiovascular Disease (CVD)
    • 5.5.1. Cardiovascular disease (CVD) market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Musculoskeletal Disorders
    • 5.6.1. Musculoskeletal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Dermatology
    • 5.7.1. Dermatology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Country Business Analysis by Therapy Type, Therapeutic Area

  • 6.1. Country Dashboard
  • 6.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
  • 6.3. Asia Pacific
    • 6.3.1. Asia Pacific cell therapy market, 2018 - 2030 (USD Million)
    • 6.3.2. Japan
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Japan cell therapy market, 2018 - 2030 (USD Million)
    • 6.3.3. China
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. China cell therapy market, 2018 - 2030 (USD Million)
    • 6.3.4. India
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. India cell therapy market, 2018 - 2030 (USD Million)
    • 6.3.5. Australia
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Australia cell therapy market, 2018 - 2030 (USD Million)
    • 6.3.6. South Korea
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. South Korea cell therapy market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2024
  • 7.4. Company Profiles/Listing
    • 7.4.1. Kolon TissueGene, Inc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. JCR Pharmaceuticals Co., Ltd.
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. MEDIPOST
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. PHARMICELL Co., Ltd.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. ANTEROGEN. CO., LTD
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Bristol-Myers Squibb Company
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Novartis AG
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Gilead Sciences, Inc.
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Curocell, Inc.
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. JW Therapeutics (Shanghai) Co., Ltd.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. STEMPEUTICS RESEARCH PVT LTD
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
Show more
Product Code: GVR-4-68039-450-4

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Asia Pacific cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 3 Asia Pacific cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 4 Asia Pacific cell therapy market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 5 China cell therapy market, by therapy type, 2018 - 2030 (USD
  • Table 6 China cell therapy market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 7 Japan cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 8 Japan cell therapy market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 9 India cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 10 India cell therapy market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 11 South Korea cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 12 South Korea cell therapy market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 13 Australia cell therapy market, by therapy type, 2018 - 2030 (USD Million)
  • Table 14 Australia cell therapy market, by therapeutic area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Asia Pacific cell therapy market: market outlook
  • Fig. 7 Asia Pacific Cell Therapy Market Competitive Insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Asia Pacific cell therapy market driver impact
  • Fig. 10 Asia Pacific cell therapy market restraint impact
  • Fig. 11 Asia Pacific cell therapy market: Therapy Type movement analysis
  • Fig. 12 Asia Pacific cell therapy market: Therapy Type outlook and key takeaways
  • Fig. 13 Allogeneic Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Stem Cell Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Hematopoietic Stem Cell Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Mesenchymal Stem Cell Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Non-stem Cell Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Keratinocytes & Fibroblast-based Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Autologous Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Stem Cell Therapies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 BM, Blood, & Umbilical Cord-derived Stem Cells market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Adipose derived cells market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Non-Stem Cell Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 T-Cell Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 CAR T Cell Therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 T Cell Receptor (TCR)-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Asia Pacific cell therapy market: Therapeutic area movement analysis
  • Fig. 31 Asia Pacific cell therapy market: Therapeutic area outlook and key takeaways
  • Fig. 32 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Cardiovascular Disease (CVD) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Musculoskeletal Disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Dermatology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Asia Pacific cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Japan cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 India cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Australia cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!